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Abstract
Background and Aim
Angiogenesis is emerging as a pivotal process in chronic inflammatory pathologies, promot-
ing immune infiltration and prompting carcinogenesis. Ulcerative Colitis (UC) and Crohn’s
Disease (CD) represent paradigmatic examples of intestinal chronic inflammatory condi-
tions in which the process of neovascularization correlates with the severity and progres-
sion of the diseases. Molecules able to target the angiogenesis have thus the potential to
synergistically affect the disease course. Beyond its anti-inflammatory effect, palmitoyletha-
nolamide (PEA) is able to reduce angiogenesis in several chronic inflammatory conditions,
but no data about its anti-angiogenic activity in colitis have been produced, yet.
Methods
The effects of PEA on inflammation-associated angiogenesis in mice with dextran sulphate
sodium (DSS)-induced colitis and in patients with UC were assessed. The release of Vascu-
lar Endothelial Growth Factor (VEGF), the hemoglobin tissue content, the expression of
CD31 and of phosphatidylinositol 3-kinase/Akt/mammalian-target-of-rapamycin (mTOR)
signaling axis were all evaluated in the presence of different concentrations of PEA and
concomitant administration of PPAR-α and -γ antagonists.
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Results
Our results demonstrated that PEA, in a selective peroxisome proliferator activated receptor
(PPAR)-α dependent mechanism, inhibits colitis-associated angiogenesis, decreasing
VEGF release and new vessels formation. Furthermore, we demonstrated that the mTOR/
Akt axis regulates, at least partly, the angiogenic process in IBD and that PEA directly
affects this pathway.
Conclusions
Our results suggest that PEA may improve inflammation-driven angiogenesis in colonic
mucosa, thus reducing the mucosal damage and potentially affecting disease progression
and the shift towards the carcinogenesis.
Introduction
Angiogenesis is the process of new vessels development from preexisting vasculature in adult
tissues and it is emerging as pivotal in the pathogenesis and progression of chronic inflamma-
tory pathologies [1–4].
There is evidence that angiogenesis contributes to a significant dysfunction of vessel archi-
tectures, promotes the recruitment of pro-inflammatory cells, and results in a progressive loss
of the epithelial integrity [5,6]. Inflammatory bowel diseases (IBD), such as Crohn’s disease
(CD) and ulcerative colitis (UC) are paradigmatic examples of chronic inflammatory diseases
in which angiogenesis-related factors affect diseases’ progression and severity [5–8].
A variegate class of signaling molecules/cytokines, involved in inflammation and tissue
remodeling processes, co-promotes angiogenesis, such as nitric oxide (NO) or prostaglandins
(PGs), but a prominent role has been identified for Vascular Endothelial Growth Factor A
(VEGF). This mediator, through the activation of a complex signaling network, yields to neo-
vascularization, worsening tissue damage and promoting the carcinogenic drift [9–10]. In
keeping with this, the inhibition of angiogenetic process may represent a potential therapeutic
target in IBDs, acting on both inflammation and carcinogenic risk [11,12].
Although the release of VEGF is regulated by different molecular pathways, the upstream
activation of phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) sig-
naling axis (Akt/mTOR pathway) has been recognized as pivotal in VEGF-related neovascular-
ization. Indeed, the activation of this pathway determines also the overexpression of the
Hypoxia-Inducible Factor (HIF)-1α, a specific transcriptional factor, which, in turn, further
increases the release of VEGF [12,13]. This complex network, is physiologically induced by
hypoxia in order to guarantee the appropriate tissue oxygenation, stimulating vessels forma-
tion, however a pathological over-activation of this pathway has been also described in differ-
ent inflammatory diseases and several tumors [14,15].
Palmitoylethanolamide (PEA) is an N-acylethanolamide (NAE), structurally and function-
ally related to anandamide (AEA), with anti-inflammatory and analgesic activities. The anti-
inflammatory effect of PEA depends on its ability to activate peroxisome proliferator activated
receptor (PPAR)-α, a member of nuclear hormone receptor superfamily of ligand activated
transcription factors [16,17]. In both mice and human colitis, PEA has been reported to
decrease the release of several pro-inflammatory cytokines [18–20], and there are data suggest-
ing that PEA also exerts a significant anti-angiogenic activity in other chronic inflammatory
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conditions [21, 22]. However, we recently demonstrated that PEA is able to directly reduce the
release of pro-angiogenic factors in an “in vitro” model of colon cancer cells [23]. The potential
anti-angiogenic activity of PEA during colitis has never been reported, yet. With the present
study we aimed to evaluate the ability of PEA to reduce the inflammation-related angiogenesis
in the colon of mice with dextran sulphate sodium (DSS)-induced colitis and in UC patients,
and to characterize its mechanisms of action.
Materials and Methods
Animals and experimental design
Six-weeks-old wild-type (WT) male CD-1 mice (Harlan Laboratories, Udine, Italy) were
used for experiments. All procedures on mice were approved by La Sapienza University's
Ethics Committee. Animal care was in compliance with the IASP and European Community
(EC L358/1 18/12/86) guidelines on the use and protection of animals in experimental
research. Animals were randomly divided into six groups (n = 10 per group): non-colitic
control group; colitic group; colitic group receiving PEA 2 and 10 mg/kg, [24, 25]; colitic
group receiving PEA (10 mg/kg) and selective PPAR-α antagonist MK866 (10 mg/kg); coli-
tic group receiving PEA and selective PPAR-γ antagonist GW9662 (1 mg/kg) [26]. Two
internal control groups (n = 5 per group) were also considered: colitic group receiving
PPAR-α or PPAR-γ antagonist; non-colitic group receiving daily PEA 10 mg/kg. Immuno-
histochemistry was performed on five groups, excluding colitic group receiving the lowest
dosage of PEA.
Colitis was induced by administrating 4% DSS (MP Biomedicals, Solon, Ohio, USA) in
drinking water for six consecutive days. PEA alone, or combined with PPAR antagonists, was
given by intraperitoneal administration from day 2 to 6 and then animals were sacrificed at day
7 by carbon dioxide inhalation followed by cervical dislocation. Colons were isolated to per-
form histochemical and biochemical analyses as described below.
In order to further confirm the involvement of PPAR-α in mediating the effects of PEA,
additional sets of experiment were conducted in six-weeks-old wild-type PPAR-α null (KO)
mice (Taconic, Germantown, New York, USA), that were divided in the following groups: vehi-
cle; colitic; colitic receiving daily PEA 10, 50 or 100 mg/kg, n = 5 for each group, respectively.
Cultured human intestinal biopsies
The experimental group comprised 10 patients with a new diagnose of UC (4 women; age
range 21–58 years; endoscopic MAYO score>2) and 5 control subjects (3 men; age range 42–
60 years; absence of gastrointestinal symptoms) undergoing colonoscopy for colon cancer
screening. Exclusion criteria were history of cancer, use of 5-aminosalicylic acid, immunosup-
pressant, anti-platelet and anti-coagulant drugs. Also patients suffering from cardiovascular,
renal or respiratory comorbidities were excluded. All subjects received and signed an informed
consent and the Federico II University Ethical committee approved the protocol.
Four mucosal biopsies from the sigmoid region of UC patients and two biopsies from the
same site of controls were collected and cultured in FBS-supplemented Dulbecco Modified
Eagle’s Medium (DMEM) at 37°C in 5% CO2/95% air. All biopsies were cultured for 24 hours,
with or without PEA at the following concentrations 0,001, 0,01, 0,1 μM [27]. Biopsies were
then homogenized and analyzed by western blot as described below. PFA-fixed samples were
used for immunohistochemistry, this analysis was only performed on biopsies stimulated with
the highest dosage of PEA (0,1 μM).
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Protein extraction and western blot analysis
Mice and human specimens were homogenized in ice-cold hypotonic lysis buffer and protein
concentration was determined using Bio-Rad protein assay kit (Bio-Rad, Milan, Italy). Analysis
of total Akt, phosphor-Akt, total mTOR, phosphor-mTOR, total p70S6K, phosphor-p70S6K,
anti-VEGF-R, anti-EGF receptor, anti-HIF1α and β-actin protein expression was performed
on total protein fractions of homogenates. Equivalent amounts of homogenates (50 μg) under-
went electrophoresis through a polyacrilamide minigel. Proteins were then transferred onto
nitrocellulose membranes that were saturated by incubation with 10% nonfat dry milk in
1× PBS overnight at 4°C and then incubated, according to the experimental protocols with:
mouse anti-total Akt (1:1000 v/v, Cell signaling technology, Euroclone, Pero, MI, Italy); rabbit
monoclonal anti phosphor-Akt (Ser 473), (1:2000 v/v, Cell signaling technology, Euroclone,
Pero, MI, Italy); rabbit polyclonal anti total mTOR (1:1000, Abcam, Cambridge, UK); rabbit
polyclonal anti phosphor-mTOR (pSer2448) (1:1000 v/v, Cell signaling technology, Euroclone,
Pero, MI, Italy); rabbit polyclonal anti total p70S6K (1:1000 v/v Cell Signaling Technology,
Euroclone, Pero, MI, Italy); and rabbit polyclonal anti-phosphor-p70S6K (Thr421/Ser424,
Thr389); (1:1000 v/v, Cell Signaling Technology, Euroclone, Pero, MI, Italy); rabbit monoclo-
nal anti-VEGF receptor (1:1000 v/v, Cell Signaling Technology, Euroclone, Pero, MI, Italy);
rabbit polyclonal anti-EGF receptor (1:1000 v/v, Abcam, Cambridge, UK); mouse monoclonal
anti-HIF1α (1:500 v/v, Sigma Aldrich, MI, Italy) and mouse anti-β-actin (1:2000 v/v, Santa
Cruz Biotechnology, Santa Cruz, California, USA). Membranes were then incubated with the
specific secondary antibodies conjugated to horseradish peroxidase (HRP) (Dako, Milan,
Italy). Immune complexes were revealed by enhanced chemiluminescence detection reagents
(Amersham Biosciences, Milan, Italy). Blots were analyzed by scanning densitometry (GS-700
imaging densitometer; Bio-Rad). Results were expressed as OD (arbitrary units; mm2) and nor-
malized on the expression of the housekeeping protein β-actin.
Enzyme-linked immunosorbent assay for VEGF and EGF
Enzyme-linked immunosorbent assay (ELISA) for VEGF (Abcam, Cambridge, UK) was car-
ried out on mice and human specimens supernatants according to the manufacturer's protocol.
Absorbance was measured on a microtitre plate reader. In a subset of experiments an ELISA
for EGF (Abcam, Cambridge, UK) was also carried out on plasma of PPAR-α null (KO) mice;
VEGF and EGF levels were thus determined using standard curves method.
Immunohistochemistry
Mice and human specimens were fixed in buffered formalin, embedded in paraffin and cut
into 5μm-thick serial sections. According to manufacturer’s instructions, after heat-mediated
antigen retrieval, the tissue was formaldehyde fixed and blocked with serum. The tissue was
incubated with the primary antibody anti CD31 (1:50 v/v, Abcam, Cambridge, UK) for 20 min-
utes. After three 5-min washes, the secondary antibody was added and the samples were incu-
bated at room temperature for 20 min. The streptavidin-HRP detection system (Chemicon
Int., Temecula, CA, USA) was added and samples were incubated at room temperature. After
three 5-min washes, 50 μL of chromogen was added and the reaction terminated after 1 min in
water. Sections were then counterstained with haematoxylin eosin at room temperature. Nega-
tive controls were performed by omitting primary antibody. Slides were thus analyzed with a
microscope (Nikon Eclipse 80i by Nikon Instruments Europe), and images were captured at
20X magnification by a high-resolution digital camera (Nikon Digital Sight DS-U1). The
amount of vascularization in each colon section was quantified as a percentage of tissue area
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immunopositive for CD31 at a 20X magnification in 6 regions, each amounting to a 0,20- mm2
area, and expressed as vessel density of (%).
Haemoglobin content measurement
As previously demonstrated, hemoglobin content measurement represents an appropriate
method for the detection and quantification of angiogenesis in tissues [28,29]. Mice and
human colonic specimens were collected and weighted, samples were then homogenized in
1 × PBS. After centrifugation at 2500 × g for 20 min at 4°C, the supernatants were further cen-
trifuged at 5000 × g for 30 min, and hemoglobin concentration in the supernatant was deter-
mined spectrophotometrically at 450 nm by the hemoglobin assay kit (Sigma Aldrich, MI,
Italy). Values were expressed as mg haemoglobin/g of wet weight.
Statistical analysis
Results were expressed as mean±SD of n experiments. Statistical analysis was performed using
parametric one-way analysis of variance (ANOVA) and multiple comparisons were performed
by Bonferroni’s posthoc test; p values<0.05 were considered significant.
Results
Mice DSS-induced colitis is associated with an increase of angiogenesis
that is inhibited by Palmitoylethanolamide
In mice with DSS-induced colitis, bloody diarrhea together with loss of body weight and
increase of spleen size were observed from day 4 until the sacrifice. As expected, the immune
infiltrate and the inflammatory mediators (NO, PGE2 and TNFα) were also significantly
increased in treated mice (data not shown).
Hemoglobin tissue content and the expression of CD31, a blood vessel endothelial marker,
were evaluated to detect the effect of PEA on angiogenesis. The hemoglobin content was signif-
icantly increased in mice with DSS-induced colitis compared to controls (36,6±2 vs 11,6±1,6
mgHb/gr tissue; p<0,0001), but such increase was significantly reduced in mice receiving PEA
(2 and 10 mg/kg) in a dose-dependent fashion (-36% and -60%, respectively; all p<0,001, Fig
1A). Co-administration of the PPAR-α antagonist, MK866, but not PPAR-γ antagonist,
GW966, significantly reverted the effects of PEA on hemoglobin content, likely indicating the
selective involvement of PPAR-α (Fig 1A).
A significant higher density of CD31 positive cells was also observed in the inflamed mucosa
of DSS-treated mice compared to controls, and, in line with the above described results, this
was significantly inhibited by PEA in PPAR-α dependent mechanism (Fig 1B).
In order to evaluate whether VEGF regulates the inflammatory-related angiogenesis in mice
colitis and if PEA may directly affect this specific pathway, we assessed the release of VEGF
and the expression of its receptor (VEGF-R). As expected, in DSS-treated mice the release of
VEGF was significantly higher than in controls, and this was associated with an increased
expression of VEGF-R (18,7±6,2 vs 137,5±14 pg/mL and 1,25±0,5 vs 5,27±0,7 ODmm2,
respectively; all p<0,0001; Fig 1C and 1D). Again, the administration of PEA (2 and 10 mg)
significantly inhibited the release of VEGF and the expression of its receptor in a dose-depen-
dent manner (-32 and -72%, -33 and -66% vs DSS-treated mice, respectively; all p<0,001, Fig
1C and 1D), and this effect was significantly affected by MK866, but not by GW9662, co-
administration (Fig 1C and 1D).
In Fig 2 it is summarized that PEA failed to induce any significant effect in DSS-treated
PPAR-α null mice, further supporting the specific involvement of PPAR-α.
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Palmitoylethanolamide inhibits the angiogenesis in the mucosa of
patients with UC
In order to verify the effect of PEA in the context of human colonic inflammation we per-
formed the same experimental protocol on mucosal biopsies from UC patients. As previously
reported [6,28,29], in the mucosa of UC patients the concentration of hemoglobin was higher
than in controls (43±6 vs 11,8±3 mgHb/g tissue p<0,001, Fig 2A) and challenge with PEA
induced a significant reduction of at hemoglobin content, in a dose dependent manner (-33,
-55 and -67%, for 0,001, 0,01 and 0,1 μM respectively; all p<0.01, Fig 2A). Similarly to what
observed in the inflamed colon of mice, 0,1 μM of PEA were also able to significantly reduce
the number of CD31 positive cells in the mucosa of patients with UC (-50%; p<0,001, Fig 2B).
As compared to control biopsies, the release of VEGF and the expression of its receptor
were also significantly increased in the mucosa from UC patients (191,6±12 vs 41,6±8 pg/mL
and 10±0,8 vs 0,5±0,1 ODmm2, respectively; all p<0,001, Fig 2C and 2D). Again, the chal-
lenge with PEA was demonstrated to induce a significant and dose-dependent reduction of
both VEGF release and VEGFR expression (-37, -53 and -70%, and -30, -50 and -70%, for
0,001, 0,01 and 0,1 μM respectively; all p<0,001, Fig 2C and 2D). Similarly to what observed in
the mice all the above described effects of PEA were dependent by PPAR-α since co-
Fig 1. Palmitoylethanolamide (PEA) inhibits colitis-associated angiogenesis in mice. (A) DSS-induced
colitis caused a significant increase of Hb-content in colonic mucosa, PEA is able to reduce, in a dose-
dependent fashion, the Hb-content in colitis mice; this effect persisted in presence of PPARγ antagonist
(GW9662) while it was nullified by PPARα antagonist (MK866). (B) Immunohistochemical images showing
the expression of CD31 on untreated mice colonic mucosa (panel 1), DSS-treated mice colonic mucosa
(panel 2), DSS-treated mice colonic mucosa in presence of PEA (10 mg/Kg) alone (panel 3), PEA (10 mg/
Kg) plus MK866 10 mg/Kg (panel 4), and PEA (10 mg/Kg) plus GW9662 1 mg/Kg (panel 5). Magnification
20X; scale bar: 100μm. The graph summarizes the relative quantification of CD31 expression (%) on mice
colonic mucosa in the same experimental groups, showing the reduction of CD31 expression in colitic mice
after PEA administration, except for the group also treated with the antagonist of PPARα. (C) VEGF release
resulted increase in DSS-treated mice and it was significantly reduced by PEA treatment in a PPARα
dependent manner. (D)Western blot analysis and relative densitometric analysis (arbitrary units normalized
on the expression of housekeeping protein β-actin) of VEGF-receptor (VEGF-R) expression, showing similar
results to VEGF release. Results are expressed as mean±SD. *p<0.05, **p<0.01 and ***p<0.001 versus
DSS-treated mice.
doi:10.1371/journal.pone.0156198.g001
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administration of MK866, but not of GW9662 significantly inhibited its effects even at the
highest dose (Fig 2A–2D)
The anti-angiogenic effect of PEA depend upon Akt/mTOR/p70S6K and
HIF-1α pathways downregulation
In order to verify whether PEA has a direct anti-angiogenic effect or this effect was related to
its anti-inflammatory properties, we evaluated the Akt/mTOR/p70S6K pathway, that is directly
involved in the angiogenesis. In the inflamed colon of DSS-treated mice phosphor-Akt, phos-
phor-mTOR and p70S6K- phosphorylation, were significantly up-regulated, and all were dose-
dependently and significantly reduced by intraperitoneal administration of PEA (Fig 3A and
3B). The expression of the hypoxia-Inducible Factor (HIF)-1α was also significantly reduced
by -43,3 and -64% after treatment with PEA at 2 and 10 mg/kg, respectively (Fig 3A and 3B).
Similarly to what observed in the mouse colon, the expression of phosphor-Akt, -mTOR,
-p70S6K and HIF-1α were all significantly overexpressed in the mucosa of UC patients (14,7
±1,5 vs 1,4±0,7, 13±1 vs 1,4±0,3, 12±0,8 vs 1±0,4 and 8,5±2,7 vs 0,4±0,1 OD = mm2, respec-
tively vs. control; all p<0,001; Fig 3C and 3D), and they were significantly reduced by PEA in a
dose-dependent fashion (all p<0,001, Fig 3C and 3D).
In both mouse and human specimens the ability of PEA to reduce the overexpression of
Akt/mTOR/p70S6K and HIF-1α pathways was significantly inhibited by concomitant admin-
istration of MK866 but not of GW9662, further supporting the concept that its effect involves
the PPARα activation (Fig 4A–4D). This finding was also supported by the observation that
Fig 2. PEA had no effects on colitis-associated angiogenesis in PPARα null (KO) mice. (A) DSS-
induced colitis caused a significant increase of Hb-content in colonic mucosa compared to untreated group,
PEA at different concentrations (10–100 mg/kg) did not show any effect on the Hb-content in colitis PPARα
(KO) mice. (B) Immunohistochemical images showing the expression of CD31 on untreated (panel 1), DSS-
treated (panel 2), and DSS-treated mice in presence of PEA (10 mg/Kg) (panel 3), PEA (50 mg/Kg) (panel 4)
and PEA (100 mg/Kg) (panel 5). Magnification 20X; scale bar: 100μm. The graph summarizes the relative
quantification of CD31 expression on mice colonic mucosa in each respective group of mice, and shows the
lack of any significant effect of PEA in reducing CD31 expression in colitic PPARα null mice. In PPARα null
mice, DSS-treatment significantly increased the release of VEGF (C) and EGF (D) and these were
unchanged by PEA administration, regardless of the concentrations used. (E) Western blot analysis and
relative densitometric analysis (arbitrary units normalized on the expression of housekeeping protein β-actin)
of VEGF-receptor (VEGF-R) and EGF-receptor (EGF-R) expression, showing similar results to VEGF and
EGF release. Results are expressed as mean±SD. ***p<0.001 versus untreated mice.
doi:10.1371/journal.pone.0156198.g002
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PEA failed to significantly affect the Akt/mTOR/p70S6K and HIF-1α pathways in PPARα null
mice (Fig 5).
Discussion
Current therapies for inflammatory bowel disease are still challenging because of the relatively
high rate of failure, the high costs and the risk of severe side effects due to immunosuppressive
agents [30,31]. New molecules able to target different steps and pathways of the inflammatory
response appear therefore a promising strategy for the treatment of these diseases.
Angiogenesis has been recently identified as a key event in the context of intestinal inflam-
mation, whose extent significantly correlates with both the severity and the progression of the
diseases [5–8], and favors the drift toward colonic carcinogenesis [32]; inhibition of angiogene-
sis appears thus as a synergistic and promising therapeutic strategy in IBDs [33,34].
VEGF is implicated in the regulation of the angiogenic process in sustained inflammation,
and contributes to mucosal tissue remodeling, vascular permeability and leukocyte infiltration
of the inflamed mucosa [35–37]. Here we demonstrated that, both in vivo and in ex vivo, PEA,
in a concentration dependent manner, significantly reduced VEGF release and the expression
of its receptor, in mice and human inflamed colon, respectively; this result was also associated
with a significant decrease of mucosal hemoglobin content and CD31 positive vessels density.
Fig 3. Effects of palmitoylethanolamide (PEA) onmolecular markers of angiogenesis in human. (A)
Ulcerative colitis caused a significant increase of Hb-content in colonic mucosa, PEA is able to reduce, in a
dose-dependent fashion, the Hb-content in colitis patients; this effect persisted in presence of PPARγ
antagonist (GW9662) while it was nullified by PPARα antagonist (MK866). (B) Immunohistochemical images
showing the expression of CD31 on: colonic mucosa of controls (panel 1), UC patients colonic mucosa
(panel 2), UC patients colonic mucosa in presence of PEA (0,1 μM) alone (panel 3), PEA (0,1 μM) plus
MK866 3 μM (panel 4), and PEA (0,1 μM) plus GW9662 (9nM) (panel 5). Magnification 20X; scale bar:
100μm. The graph summarizes the relative quantification of CD31 expression (%) on human colonic mucosa
in the same experimental groups, and, as described in mice, PEA administration caused a significant
reduction of CD31 expression, except after co-administration of PPARα antagonist. (C) VEGF release
resulted increase in uncreative colitis patients and it was significantly reduced by PEA treatment in a PPARα
dependent mannerD)Western blot analysis and relative densitometric analysis (arbitrary units normalized on
the expression of housekeeping protein β-actin) of VEGF-receptor (VEGF-R) expression, showing a similar
behavior to VEGF release. Results are expressed as mean±SD. *p<0.05, **p<0.01 and ***p<0.001 versus
untreated biopsies from ulcerative colitis patients.
doi:10.1371/journal.pone.0156198.g003
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Fig 4. Effects of palmitoylethanolamide (PEA) on Akt/mTOR/p70S6K axis activation and HIF-1α
expression in DSS-induced colitis and in ulcerative colitis. (A)Western Blot analysis and (B) relative
densitometric analysis showing the effects of PEA (2 mg/Kg and 10 mg/Kg), given alone or in the presence of
MK866 (10 mg/Kg) or GW 9662 (1 mg/Kg), on the expression of phosphor-Akt, phosphor-mTOR, phosphor-
p70S6K and HIF-1α in mice with DSS-induced colitis. Western blot analysis (C) and relative densitometric
analysis showing the effects of PEA at increasing concentration (0.001 μM, 0.01 μM and 0.1 μM) given alone
and in the presence of MK866 (3 μM) or GW9662 (9 nM), on the expression of phosphor-Akt, phosphor-
mTOR, phosphor-p70S6K and HIF-1α in UC patients biopsies. In both human and mice, colitis induced the
activation of pro-angiogenic Akt/mTOR/p70S6K pathway, and PEA resulted able to reduce it, in a dose-
dependent and PPARα dependent fashion. Results are expressed as mean ± SD. *p<0.05, **p<0.01 and
***p<0.001 versus DSS-treated mice (A and B) or vs untreated colonic biopsies from UC patients (C and D).
doi:10.1371/journal.pone.0156198.g004
Fig 5. Palmitoylethanolamide (PEA) failed to significantly affect DSS-induced Akt/mTOR/p70S6K axis
activation and HIF-1α expression in PPARα null (KO) mice. (A)Western Blot analysis and (B) relative
densitometric analysis showing the effects of PEA (10–100 mg/kg) on the expression of phosphor-Akt,
phosphor-mTOR, phosphor-p70S6K and HIF-1α in DSS-treated PPARα null (KO) mice. DSS exposure
significantly induced the activation of the pro-angiogenetic Akt/mTOR/p70S6K pathway as compared to
untreated mice, but treatment with PEA had no significant effect in treated mice, regardless of the
concentration used. Results are expressed as mean ± SD. ***p<0.001 versus untreated mice.
doi:10.1371/journal.pone.0156198.g005
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It has been described that PEA is able to exert an antiangiogenic activity in other experimen-
tal models of chronic inflammation, likely supporting the concept that this ability is dependent
by its anti-inflammatory effects [21,22,38]. However, we recently demonstrated that PEA
directly reduces the release of pro-angiogenic factors in an in vitro model of colon cancer cells,
through an Akt-mTOR pathway-dependent VEGF inhibition; these results suggest that the
anti-angiogenic activity displayed by PEA in the inflamed colon is not solely related by its anti-
inflammatory effects [23].
In our setting, we therefore investigated whether PEA-dependent VEGF signaling inhibition
modulated by the AkT/mTOR axis. Different molecular pathways are involved in the angiogen-
esis, but the activation of AkT/mTOR axis has been specifically related to neo-vascularization in
the development of inflammation-sustained colon cancer [39–41]. In particular, it induces the
over-expression of HIF-1α, a transcriptional factor related to hypoxia, that cooperates with reac-
tive oxygen species (ROS), stimulating the release of VEGF and eventually neo-angiogenesis
[42–44]. Our results demonstrated that PEA, in a PPAR-α selective and concentration depen-
dent-manner, significantly reduced the phosphorylation of Akt, mTOR and p70S6 proteins in
mice colon and ex-vivo human mucosa, leading to downstream inhibition of HIF-1α with con-
sequent inhibition of VEGF and EGF secretion and the respective receptors expression.
Remarkably, here we also showed that all the above-described pleiotropic effects of PEA are
specifically related to the activation of the PPAR-α pathway. Although the role of PPAR-γ as
putative site of action of anti-inflammatory and anti-cancer drugs has been specifically
addressed [45,46], the importance of PPAR-α pathway is recently emerging [16,23,27]. In
keeping with this, we have demonstrated that the inhibition of the mTOR/AkT axis depends
on PPAR-α activation, supporting its contribution in IBD-related angiogenesis and suggesting
its protective role in inflammation-associated carcinogenesis. In addition, we provide data sug-
gesting that PEA is able to act on the process of angiogenesis by directly modulating the endo-
thelial cell’s functioning, as demonstrated by its effect to significantly inhibit inflammatory-
associated proliferation and migration of HUVEC cells (S1 Fig).
As stated, anti-angiogenetic drugs represent an intriguing approach to treat IBDs, due to the
effect on both inflammation and tumorigenesis. However, the efficacy of anti-angiogenic drugs
is limited by the complexity and redundancy of the molecular pathways converging in neovas-
cularization. In this context, PEA appears as a very interesting compound, since together with
its activity on the AkT/mTOR pathway, it also significantly reduces the p38/MAPK/NF-kB
axis [47–49]. It has been indeed previously demonstrated that PEA is able to inhibit the NF-kB
(nuclear factor kappa-light-chain-enhancer of activated B cells) pro-inflammatory pathway,
determining a strong downregulation of cyclooxygenase (COX)-2 and inducible nitric oxide
synthase (iNOS) expression, with a consequent reduction of prostaglandins and nitric oxide
release [48, 49]. While the role of these mediators in the inflammatory process is well estab-
lished, there is evidence about their involvement in neo-vascularization and tumor growth,
supporting the inflammation-associated carcinogenesis assumption [50, 51]. Interestingly,
besides such anti-angiogenic and anti-inflammatory activity, PEA, as the others cannabinomi-
metic fatty acid derivatives, also exerts an antiproliferative effect on cancer cells, supporting its
protective effects in both inflammation and cancer prevention [23, 52, 53].
To date, mesalamine is the unique drug, widely used in IBD, with both anti-inflammatory
and potential anti-carcinogenic proprieties [54, 55]. However, even if rare, severe side effects to
this compound, such as pancreatitis and interstitial nephritis, have been described [56]. PEA is
a safe drug with a well known toxicological profile and it is already available as orally adminis-
tered supplement in clinical practice [57, 58].
Although further studies are needed, palmitoylethanolamide, due to its anti-inflammatory
and anti-angiogenic effects, might represent a promising “food therapy” for the prevention of
Antiangiogenic Effect of Palmitoylethanolamide in Colitis
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inflammation-associated colon cancer, and, most importantly, be part of a combined and
multi-target therapy in the management of inflammation-associated angiogenesis and the
potential anti-carcinogenic activity.
Supporting Information
S1 Fig. Palmitoylethanolamide reduced migration and proliferation in DSS-treated
HUVEC cells.
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